In this episode, Etienne Nichols sits down with regulatory expert Mike Drues, President of Vascular Sciences, to discuss the "culture shock" international medical device companies face when entering the U.S. market. They challenge the traditional assumption that a device should always launch outside the U.S. first, noting that shifting regulatory landscapes—especially in Europe—have made the U.S. a more attractive primary entry point for many.

The conversation pivots to the technical and strategic nuances of "same device, different claims." Mike explains that if a device maintains the same design but utilizes different labeling or indications for use across borders, it is technically a different device in the eyes of regulators. This creates significant complexity for Quality Management Systems and post-market surveillance, particularly concerning reporting requirements for Class III (PMA) devices.

Finally, the duo explores the "trap of equivalency," where companies mistakenly assume that a CE Mark or other international approval guarantees a smooth path through the FDA. From differing consensus standards to the strategic use of OUS (Outside US) clinical data, the episode provides a roadmap for global players to synchronize their regulatory and reimbursement strategies early in the development lifecycle.

Key Timestamps

1. 01:45 - Challenging the assumption: Should you always launch outside the US first?
2. 04:12 - Defining the "International Company": Why every developer should think globally from day one.
3. 05:30 - The Labeling Trap: Why the same hardware with different claims is a different device.
4. 07:50 - Post-market surveillance nuances: Reporting OUS issues in a US PMA submission.
5. 11:15 - The "Sniff Test": Does a CE Mark actually help you with the FDA?
6. 12:40 - Leveraging Real-World Evidence (RWE) from international markets for US submissions.
7. 14:30 - The "Species Expansion" concept: Applying regulatory logic across different use cases.
8. 16:15 - Consensus Standards: Why the FDA might not recognize the "most current" version of a standard.
9. 20:00 - International Regulatory Strategy: Calculating the "lowest common denominator" for multi-country launches.
10. 25:20 - Using 100% OUS clinical data for FDA submissions: The three essential caveats.

Quotes

"If you’re marketing the same device—same design, same materials—but the labeling and claims are different in the EU versus the US, then technically, it is not the same device." - Mike Drues

"The regulatory logic is agnostic of the scenario. Whether it's a label expansion or a 'species expansion' from a dog to a human, the underlying logic remains the same." - Mike Drues

Takeaways

1. Sync Your Standards: Do not assume the FDA recognizes the same version of a standard (e.g., ISO 10993-1) as international bodies. Always verify via the CDRH Recognized Consensus Standards database.
2. Design for the "Lowest Common Denominator": Identify your top 3–5 target markets early and pool their requirements to avoid redundant benchtop or clinical testing.
3. Rethink Clinical Trials: While the FDA prefers domestic data, OUS data can be used if you can prove the patient population and user profiles (physicians/nurses) are representative of the US demographic.
4. Anticipate "Off-Label" Pressure: If you market a device in Canada with claims not yet approved in the US, be prepared for US clinicians to find that information online and ask for "anticipated off-label use."

References

1. FDA Recognized Consensus Standards Database: Essential tool for verifying which versions of international standards the FDA currently accepts.
2. Greenlight Guru QMS & EDC: Solutions for managing complex, multi-region quality systems and clinical data.
3. Etienne Nichols’ LinkedIn: Connect with the host for more MedTech insights.

MedTech 101: Label Expansion

Think of Label Expansion like a smartphone software update. The hardware (the phone) stays the same, but the update allows the phone to do something it couldn't do before—like a new photography mode. In MedTech, if you have a stent approved for use in the leg (the "old label") and you want to use that same stent in the heart, you apply for a "label expansion." You aren't changing the device; you're just proving it’s safe and effective for a new job.

Sponsors: Greenlight Guru

This episode is brought to you by Greenlight Guru. Navigating international waters requires a robust foundation. Greenlight Guru’s Quality Management Software (QMS) helps you maintain a "single source of truth" for your design history files and labeling, while their Electronic Data Capture (EDC) solution streamlines the collection of the clinical data you'll need to satisfy both the FDA and international regulators. Whether you are managing post-market surveillance for a PMA or running a multi-center global trial, Greenlight Guru has you covered.

Feedback Call-to-Action

We want to hear from you! Did this episode change your mind about your international launch strategy? Do you have a "culture shock" story from bringing a device to the US? Send your thoughts, reviews, or topic suggestions to podcast@greenlight.guru. We read every email and love providing personalized responses to our listeners.